AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25712298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23608246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline starting on the day of HCG injection
Number of subjects: 206
Study 23608246 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline starting on the day of oocyte retrieval
Number of subjects: 206
Study 21279990 — intervention group
Group type: EXPERIMENTAL
Intervention: R788 (fostamatinib disodium) 100 mg twice daily
Number of subjects: 219
Study 21279990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 18640170 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 vaccine (3 doses)
Number of subjects: 7466
Study 18640170 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 7466
Study 17055909 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 60
Study 17055909 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite resin
Number of subjects: 60
Study 17055909 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycarboxylate cement
Number of subjects: 60
Study 17055909 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement
Number of subjects: 60
Study 17055909 — intervention group
Group type: COMPARATOR
Intervention: No barrier material (group 5)
Number of subjects: 60
Study 14641395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone calls intervention applied for 12 weeks, consisting of education and reinforcement of diet, exercise, medication adjustment recommendations, and self-monitoring of blood glucose levels.
Number of subjects: 36
Study 14641395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nurse telephone calls)
Number of subjects: 36
Study 11739980 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 72
Study 11739980 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 9241127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles
Number of subjects: 141
Study 9241127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 7510990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 7510990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3524231 — intervention group
Group type: EXPERIMENTAL
Intervention: mazindol (2 mg daily)
Number of subjects: 2
Study 3524231 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study 29766770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 503
Study 29766770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 27083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful decision‐making training (MDT)
Number of subjects: 119
Study 27083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (ICT)
Number of subjects: 119
Study 27083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MDT and ICT
Number of subjects: 119
Study 27083129 — intervention group
Group type: COMPARATOR
Intervention: Neither (psychoeducation)
Number of subjects: 119
Study 25402490 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 150
Study 25402490 — intervention group
Group type: COMPARATOR
Intervention: Beta interferons
Number of subjects: 150
Study 23748117 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 76
Study 23748117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23748117 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 76
Study 20453504 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual sampling method
Number of subjects: 35
Study 20453504 — intervention group
Group type: COMPARATOR
Intervention: Pooled sampling method
Number of subjects: 35
Study 18771833 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based microfinance combined with participatory gender and HIV training
Number of subjects: 845
Study 18771833 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified in detail)
Number of subjects: 845
Study 17240933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste with dental floss
Number of subjects: 114
Study 17240933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste without dental floss
Number of subjects: 114
Study 17240933 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride toothpaste with dental floss
Number of subjects: 114
Study 12678189 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 60
Study 12678189 — intervention group
Group type: COMPARATOR
Intervention: tirofiban
Number of subjects: 60
Study 10641576 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 14
Study 10641576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8705740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (cyanoacrylate)
Number of subjects: 0
Study 8705740 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor suture
Number of subjects: 0
Study 8705740 — intervention group
Group type: COMPARATOR
Intervention: No suture (unsutured group)
Number of subjects: 0
Study 8705740 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (suture, tissue adhesive, unsutured)
Number of subjects: 0
Study 1889143 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pirenzepine
Number of subjects: 16
Study 1889143 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine
Number of subjects: 16
Study 1889143 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pirenzepine at night
Number of subjects: 16
Study 1889143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3902672 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 20 mg once daily
Number of subjects: 16
Study 3902672 — intervention group
Group type: COMPARATOR
Intervention: Timolol 10 mg twice daily
Number of subjects: 16
Study 29055257 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole
Number of subjects: 1056
Study 29055257 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 1056
Study 26850264 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 206
Study 26850264 — intervention group
Group type: COMPARATOR
Intervention: Facet blocking (FB)
Number of subjects: 206
Study 26850264 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP
Number of subjects: 206
Study 26850264 — intervention group
Group type: COMPARATOR
Intervention: FB
Number of subjects: 206
Study 26850264 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP and FB
Number of subjects: 206
Study 25245821 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with bevacizumab (n=10)
Number of subjects: 21
Study 25245821 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin without bevacizumab (n=11)
Number of subjects: 21
Study 23207862 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lacebacks (Group 1)
Number of subjects: 23
Study 23207862 — intervention group
Group type: COMPARATOR
Intervention: Passive lacebacks (Group 2)
Number of subjects: 23
Study 20189174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhibitai (480 mg orally twice daily)
Number of subjects: 169
Study 20189174 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg orally once a day)
Number of subjects: 169
Study 20189174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Zhibitai and Atorvastatin
Number of subjects: 169
Study 18569754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 286
Study 18569754 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Counseling
Number of subjects: 286
Study 17379054 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10-microg BID after initial 5-microg BID for 4 weeks
Number of subjects: 283
Study 15497510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro (n=11)
Number of subjects: 21
Study 15497510 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (n=10)
Number of subjects: 21
Study 10884452 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis using alteplase
Number of subjects: 150
Study 9050118 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions
Number of subjects: 97
Study 9050118 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 97
Study 9050118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-EE families with cannabis abuse
Number of subjects: 97
Study 8313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (360 mg in 5 days and 480 mg in 7 days)
Number of subjects: 101
Study 8313183 — intervention group
Group type: COMPARATOR
Intervention: Piperaquine phosphate
Number of subjects: 101
Study 3539601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 100
Study 3539601 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 100
Study 31122494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with cilostazol (100 mg, twice per day) and aspirin or clopidogrel
Number of subjects: 1884
Study 31122494 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with aspirin (81 or 100 mg, once per day) or clopidogrel (50 or 75 mg, once per day)
Number of subjects: 1884
Study 28232599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821
Study 28232599 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study 25134047 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency group (n = 35) required to ingest naltrexone under staff observation
Number of subjects: 67
Study 25134047 — intervention group
Group type: COMPARATOR
Intervention: Prescription group (n = 32) given a take-home supply of oral naltrexone
Number of subjects: 67
Study 25134047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 23782870 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual cessation support plus referral to Slimming World
Number of subjects: 320
Study 23782870 — intervention group
Group type: COMPARATOR
Intervention: Usual cessation support alone
Number of subjects: 320
Study 21716267 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg/kg) after pretreatment with ticlopidine (250 mg twice daily)
Number of subjects: 11
Study 21716267 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg/kg) after pretreatment with itraconazole (200 mg once daily)
Number of subjects: 11
Study 21716267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21716267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine and Itraconazole phases
Number of subjects: 11
Study 16833023 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg risperidone tablet
Number of subjects: 24
Study 16833023 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*10 allele
Number of subjects: 24
Study 12768907 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil
Number of subjects: 80
Study 12768907 — intervention group
Group type: COMPARATOR
Intervention: Propofol/Fentanyl/Alfentanil
Number of subjects: 80
Study 11048829 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose infusion
Number of subjects: 81
Study 11048829 — intervention group
Group type: COMPARATOR
Intervention: No glucose infusion (control)
Number of subjects: 81
Study 9070546 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 37
Study 9070546 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 37
Study 8375090 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpropagation neural networks trained on clinical data
Number of subjects: 807
Study 8375090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation monitoring during training
Number of subjects: 807
Study 3740576 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call by an ED nurse two to three days after discharge
Number of subjects: 297
Study 3740576 — intervention group
Group type: COMPARATOR
Intervention: No follow-up telephone call (control group)
Number of subjects: 297
Study 29283072 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 144
Study 29283072 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 144
Study 30165765 — intervention group
Group type: COMPARATOR
Intervention: Horizontal table position
Number of subjects: 270
Study 30165765 — intervention group
Group type: COMPARATOR
Intervention: 7° head-down table position
Number of subjects: 270
Study 30165765 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific table position based on correction of pelvic adduction
Number of subjects: 270
Study 26452698 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic-ECT time interval
Number of subjects: 84
Study 24930870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF)
Number of subjects: 130
Study 24930870 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 130
Study 22901346 — intervention group
Group type: COMPARATOR
Intervention: Lu AA21004 10 mg
Number of subjects: 560
Study 22901346 — intervention group
Group type: COMPARATOR
Intervention: Lu AA21004 1 mg
Number of subjects: 560
Study 22901346 — intervention group
Group type: COMPARATOR
Intervention: Lu AA21004 5 mg
Number of subjects: 560
Study 22901346 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 560
Study 20445497 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral sodium bicarbonate
Number of subjects: 0
Study 20445497 — intervention group
Group type: COMPARATOR
Intervention: Placebo or equimolar sodium chloride
Number of subjects: 0
Study 18076275 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (C)
Number of subjects: 15
Study 18076275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 15
Study 18076275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (C and P)
Number of subjects: 15
Study 16052276 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg/day
Number of subjects: 223
Study 16052276 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg
Number of subjects: 223
Study 16052276 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg
Number of subjects: 223
Study 16052276 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study 11756605 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 16
Study 11756605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9715485 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone acetate
Number of subjects: 36
Study 9715485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8140111 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern dressing A
Number of subjects: 0
Study 8140111 — intervention group
Group type: COMPARATOR
Intervention: Modern dressing B
Number of subjects: 0
Study 3048953 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol)
Number of subjects: 24
Study 3048953 — intervention group
Group type: COMPARATOR
Intervention: Placebo olive oil
Number of subjects: 24
Study 29729978 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused individualized diabetic education sessions before Ramadan
Number of subjects: 320
Study 29729978 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetic care (Control)
Number of subjects: 320
Study 27063162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin, 80 mg/day, 3 days before till 3 days after intervention)
Number of subjects: 40
Study 27063162 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (atorvastatin, 20 mg/day)
Number of subjects: 40
Study 24462183 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr‐EES (PROMUS Element everolimus‐eluting stent)
Number of subjects: 1530
Study 24462183 — intervention group
Group type: COMPARATOR
Intervention: CoCr‐EES (XIENCE V everolimus-eluting stent)
Number of subjects: 1530
Study 23185751 — intervention group
Group type: EXPERIMENTAL
Intervention: CMM + chemotherapy (189 cases)
Number of subjects: 366
Study 23185751 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (177 cases)
Number of subjects: 366
Study 20400920 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of remifentanil (0.8 ng · mL as effect-site target)
Number of subjects: 22
Study 20400920 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled infusion of remifentanil (loading dose of 0.75 μg · kg and 0.075 μg · kg · min as maintenance)
Number of subjects: 22
Study 17715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E + P)
Number of subjects: 0
Study 17715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for trial monitoring
Number of subjects: 0
Study 17715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring board input
Number of subjects: 0
Study 17715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety monitoring
Number of subjects: 0
Study 17715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods in published reports
Number of subjects: 0
Study 16261287 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-135 (4.5 mg/kg/48 hours)
Number of subjects: 0
Study 16261287 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-135 (9.0 mg/kg/48 hours)
Number of subjects: 0
Study 16261287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16261287 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-135 (4.5 mg/kg/48 hours) and MCC-135 (9.0 mg/kg/48 hours)
Number of subjects: 0
Study 12239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase injection therapy (one dose)
Number of subjects: 129
Study 12239666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 12239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase injection therapy (dose-response study)
Number of subjects: 129
Study 12239666 — intervention group
Group type: COMPARATOR
Intervention: Surgical fasciectomy
Number of subjects: 129
Study 10665619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), delivered in 19 individual sessions over 9 months
Number of subjects: 90
Study 10665619 — intervention group
Group type: COMPARATOR
Intervention: Befriending control intervention, delivered in 19 individual sessions over 9 months
Number of subjects: 90
Study 8842506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg tid
Number of subjects: 56
Study 8842506 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide 250 mg tid
Number of subjects: 56
Study 8842506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 56
Study 8842506 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 56
Study 1300237 — intervention group
Group type: EXPERIMENTAL
Intervention: Seraspenide
Number of subjects: 53
Study 1300237 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 53
Study 6508975 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 5 min after drug ingestion on an empty stomach
Number of subjects: 6
Study 6508975 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 60 min after drug ingestion on an empty stomach
Number of subjects: 6
Study 6508975 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 5 min after drug ingestion after a standard meal
Number of subjects: 6
Study 6508975 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g administered 60 min after drug ingestion after a standard meal
Number of subjects: 6
Study 30753449 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-retraining based on hands-on rolling refreshers during the 2-month program (G-CPR, n = 53)
Number of subjects: 114
Study 30753449 — intervention group
Group type: COMPARATOR
Intervention: Standard one-time training (G-Stan, n = 61)
Number of subjects: 114
Study 30753449 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-retraining (G-CPR)
Number of subjects: 114
Study 29459791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-based enteral nutrition (group A, n=30)
Number of subjects: 60
Study 29459791 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based enteral nutrition (group B, n=30)
Number of subjects: 60
Study 29459791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-based enteral nutrition (group A)
Number of subjects: 60
Study 29459791 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based enteral nutrition (group B)
Number of subjects: 60
Study 26986776 — intervention group
Group type: EXPERIMENTAL
Intervention: Head elevation during videolaryngoscopy with the McGrath device
Number of subjects: 46
Study 26986776 — intervention group
Group type: COMPARATOR
Intervention: Flat head position during videolaryngoscopy with the McGrath device
Number of subjects: 46
Study 25352865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% IV dextrose infusion by burettes
Number of subjects: 140
Study 25352865 — intervention group
Group type: COMPARATOR
Intervention: 10% mini dextrose boluses
Number of subjects: 140
Study 22408122 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy
Number of subjects: 1066
Study 18690451 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) densitometry
Number of subjects: 266
Study 17991050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring by nursing and other college students
Number of subjects: 0
Study 17991050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16024305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4-8 weeks
Number of subjects: 560